TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03391245

Intervention type: DIAGNOSTIC_TEST
Intervention: 3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique
Description: Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
Study: NCT02207426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Study: NCT00501787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT02207426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Study: NCT04427982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dance
Description: Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes education
Description: The dance classes will be followed by a brief diabetes education and discussion session.
Study: NCT02551549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 IV
Description: antifungal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02182388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA tablet
Study: NCT00166413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: 40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
Study: NCT01274689

Intervention type: OTHER
Intervention: individually tailored lead weight
Description: patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
Study: NCT04312646

Intervention type: DEVICE
Intervention: Elastography .
Description: Performance of US, elastography
Study: NCT03114852

Intervention type: DIAGNOSTIC_TEST
Intervention: blood collection
Description: They will have blood tested to renal genetic diseases

Intervention type: DIAGNOSTIC_TEST
Intervention: blood collection
Description: They will have blood tested to renal genetic diseases
Study: NCT01962363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
Study: NCT00881868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray 0.05%
Description: Apply enough product to cover affected areas topically twice daily at least 8 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle spray
Description: Apply enough product to cover affected areas topically twice daily at least 8 hours apart
Study: NCT02537015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
Study: NCT04159298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Top Spin 360
Description: The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
Study: NCT01601652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 1 g/kg/d iv infusion over 24h
Study: NCT00658164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron depletion treatment
Description: Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
Study: NCT02103673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention drug: placebo by mouth. Duration: 6 weeks
Study: NCT02832362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbomer 980
Description: Test product containing 0.5% carbomer 980 gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference product containing vehicle without 0.5% carbomer 980 gel
Study: NCT03198624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Part A single dose Part B five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Part A single dose Part B five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Part A single dose Part B five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Part A single dose Part B five doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Part B only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Part B only
Study: NCT04917341

Intervention type: DIAGNOSTIC_TEST
Intervention: re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital
Description: The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.

Intervention type: DIAGNOSTIC_TEST
Intervention: re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital
Description: The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.

Intervention type: DIAGNOSTIC_TEST
Intervention: re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital
Description: The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
Study: NCT01657461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Description: Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solitaire revascularization device
Description: Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
Study: NCT00234754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT Surgery TOT Surgery
Description: TVT surgery and TOT surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT Surgery TOT Surgery
Description: TVT surgery and TOT surgery
Study: NCT01452932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them.

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention.
Study: NCT01039662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arabinose and indigestible dextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02657473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tobramycin inhalation solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% inhalation solution
Study: NCT02609113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strong Magnetic Wristband

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Weaker Magnetic Wristband
Study: NCT01213199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: Adapalene Gel 0.3%
Study: NCT00913952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Study: NCT00778843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Viusid, three oral sachets daily during 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three oral sachets daily during 24 weeks
Study: NCT03563924

Intervention type: OTHER
Intervention: Setting up a specific care path AlloTC for management of TVE in patients with cancer
Description: Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)
Study: NCT01984658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alecsat
Description: The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
Study: NCT01715012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: ST266 is applied daily by spray to burn wound and skin graft donor site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is applied daily by spray to burn wound and skin graft donor site
Study: NCT04458090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A decision aid for patients considering Hospice care.
Description: A 12 page booklet and 17 min video describing hospice care
Study: NCT00547443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given 5 days a week for 7.5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 7.5 weeks
Study: NCT03993067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fribrin glue and Tabotamp
Description: Fibrin glue and Tabotampis the standard treatment
Study: NCT04183543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields
Description: The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: Inactive Pulsed Electromagnetic Field therapy
Study: NCT02460796

Intervention type: OTHER
Intervention: Hippotherapy
Description: The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
Study: NCT03357588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified monitoring
Description: Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care monitoring
Description: Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
Study: NCT00942097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy and Nutritional oriented diet
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathy and Nutritional oriented diet
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
Study: NCT00380653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine
Study: NCT02917642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Irrigation
Description: Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Ultrasonic Irrigation
Description: Syringe and needle irrigation with no-ultrasonic activation
Study: NCT02812017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thirty Million Words- Well Baby
Description: Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Safety Starts at Home
Description: A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
Study: NCT05295667

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler measurement in combination with amniotic fluid volume
Description: Ultrasonographic evaluation
Study: NCT03945604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 + Apatinib +Fluzoparib
Description: SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
Study: NCT02767349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-155
Description: 2 or 3 tablets initial dose, followed by two tablets every twelve hours
Study: NCT00700388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPEP device (UNIKO)
Description: This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MABT (Manually assisted breathing techniques)
Description: Conventionally manually assisted breathing techniques
Study: NCT04581707

Intervention type: DEVICE
Intervention: Kyphoplasty Single Balloon Catheter Allevo
Description: Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement

Intervention type: DEVICE
Intervention: Quattroplasty Double Balloon Catheter Stop'n GO
Description: Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
Study: NCT02490670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally
Study: NCT02525770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiostereometric analysis (RSA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiostereometric analysis (RSA)
Study: NCT00552188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: 100 mg, oral dosing, 1 time daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 24 weeks
Study: NCT03867370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (JS001 )
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (JS001 ) Lenvatinib
Description: Given IV 4 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab (JS001 ) Lenvatinib
Description: Given IV 4 mg capsules
Study: NCT04534816

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Perfusion assessments
Study: NCT03353337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group
Description: General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
Study: NCT00732446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Dexamethasone combined
Description: moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: moxifloxacin 0,5% qid and

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 0,1% qid
Study: NCT02653417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04461067

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: Ultrasonography of the stomach is performed to measure the diameter of the antrum
Study: NCT04277923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: the lipid of all-in-one is less than 4g/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipofundin
Description: the lipid of all-in-one is less than 4g/kg.d
Study: NCT05033704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% human plasma protein fraction (PPF)
Description: Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).